Investor Relations

Overview

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.

read more

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates

Imsidolimab Phase 3 GPP trial anticipated to commence in mid-2021 following FDA end-of-Phase 2 meeting held during Q2 2021 JEMPERLI (dostarlimab), our PD-1 antagonist antibody partnered with GlaxoSmithKline (GSK), was approved for endometrial cancer in the US and EU during Q2 2021, earning $30

European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe

PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK) First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development , to Obtain Regulatory Approval in Europe $10MM Milestone Payment Earned by AnaptysBio Upon EC Approval;

FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer

PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK) First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development , to Obtain FDA Approval $20MM Milestone Payment Earned by AnaptysBio Upon FDA Approval; Additional $45MM